AI引领医药革命：礼来首席信息官揭示生成式AI在药物发现中的惊人潜力

金融界05-06

随着科技的不断进步，人工智能(AI)正在以前所未有的速度改变着各行各业，其中，制药行业正迎来一场由AI引领的革命。近日，礼来公司(Eli LiLLY)首席信息和数字官迪奥戈.劳(Diogo Rau)在公开场合分享了一次不同寻常的实验经历，这次实验并非在典型的制药公司实验室中进行药物研究，而是利用生成式人工智能在数百万个分子中搜索潜在药物候选物。劳的分享不仅揭示了AI在医药领域的巨大潜力，也引发了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2433341290?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-06 15:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2433341290","market":"us","top_or_hot":-1,"title":"AI引领医药革命：礼来首席信息官揭示生成式AI在药物发现中的惊人潜力","media":"金融界","content":"<div>\n<p>随着科技的不断进步，人工智能(AI)正在以前所未有的速度改变着各行各业，其中，制药行业正迎来一场由AI引领的革命。近日，礼来公司(Eli LiLLY)首席信息和数字官迪奥戈.劳(Diogo Rau)在公开场合分享了一次不同寻常的实验经历，这次实验并非在典型的制药公司实验室中进行药物研究，而是利用生成式人工智能在数百万个分子中搜索潜在药物候选物。劳的分享不仅揭示了AI在医药领域的巨大潜力，也引发了...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061545428b7905f1&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AI引领医药革命：礼来首席信息官揭示生成式AI在药物发现中的惊人潜力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAI引领医药革命：礼来首席信息官揭示生成式AI在药物发现中的惊人潜力\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-06 15:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061545428b7905f1&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>随着科技的不断进步，人工智能(AI)正在以前所未有的速度改变着各行各业，其中，制药行业正迎来一场由AI引领的革命。近日，礼来公司(Eli LiLLY)首席信息和数字官迪奥戈.劳(Diogo Rau)在公开场合分享了一次不同寻常的实验经历，这次实验并非在典型的制药公司实验室中进行药物研究，而是利用生成式人工智能在数百万个分子中搜索潜在药物候选物。劳的分享不仅揭示了AI在医药领域的巨大潜力，也引发了...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061545428b7905f1&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443549.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061545428b7905f1&s=b","article_id":"2433341290","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061545428b7905f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2433341290","pubTimestamp":1714981264,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"劳的分享不仅揭示了AI在医药领域的巨大潜力，也引发了行业内外对AI药物发现未来趋势的广泛关注。据从事AI和医疗保健交叉领域工作的高管透露，未来几年内，AI生产药物将成为药物发现的一种规范。这种数字化趋势为AI在药物发现中的应用提供了广阔的空间和无限的可能性。这些都是AI药物发现领域需要关注和解决的问题。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4588":"碎股","LU0097036916.USD":"贝莱德美国增长A2 USD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LLY":"礼来","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4581":"高盛持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"AI leads the pharmaceutical revolution: Eli Lilly CIO reveals amazing potential of generative AI in drug discovery","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"随着科技的不断进步，人工智能(AI)正在以前所未有的速度改变着各行各业，其中，制药行业正迎来一场由AI引领的革命。近日，礼来公司(Eli LiLLY)首席信息和数字官迪奥戈.劳(Diogo Rau)在公开场合分享了一次不同寻常的实验经历，这次实验并非在典型的制药公司实验室中进行药物研究，而是利用生成式人工智能在数百万个分子中搜索潜在药物候选物。劳的分享不仅揭示了AI在医药领域的巨大潜力，也引发了行业内外对AI药物发现未来趋势的广泛关注。一、AI加速药物发现，礼来实验引发热议礼来公司作为全球知名的制药企业，一直在积极探索利用AI技术提升药物研发效率和质量。劳最近参与的实验就是这一探索的生动体现。据劳介绍，AI能够以惊人的速度生成大量分子设计，这些设计在五分钟内产生的分子数量相当于礼来制药在传统实验室一整年合成的分子数量。然而，如何验证这些由AI生成的分子设计是否能在现实世界中发挥作用，成为了礼来公司高管们关注的焦点。在这次实验中，劳和团队将AI生成的顶级生物设计交给了礼来的研究科学家进行评估。这些设计被劳描述为具有“奇怪结构”的分子，无法与该公司现有的分子数据库相匹配，但看起来像是潜在的强大候选药物。劳坦言，他和团队原本预计科学家们会对这些AI设计持怀疑态度，甚至可能指出其中的错误。然而，科学家们的回应却让他们大吃一惊——他们不仅没有否定这些设计，反而认为它们非常有趣且具有潜力。二、AI药物发现：重塑制药行业与科学方法劳的分享引发了行业内外的广泛讨论。许多专家认为，AI在药物发现领域的应用不仅将大大提高研发效率和质量，还将重塑制药行业以及几个世纪以来融入科学方法的基本思想。一方面，AI能够通过分析海量的生物数据和化学信息，快速生成大量潜在的药物候选物。这种基于大数据和算法的药物设计方法相比传统的经验方法更加系统化和可重复化，能够显著提高药物研发的成功率。据从事AI和医疗保健交叉领域工作的高管透露，未来几年内，AI生产药物将成为药物发现的一种规范。另一方面，AI还能够开辟人类可能无法探索的医学发展途径。通过学习和模拟生物行为以及分子间的相互作用关系，AI能够产生出人类难以想象的药物设计。这种创造力不仅能够加速药物研发进程，还能够推动医学科学的进步和发展。三、从AlphaFold到ChatGPT：AI技术驱动生物领域数字化在礼来公司的实验之前，谷歌DeepMind的AlphaFold项目已经在生物领域引发了广泛关注。AlphaFold利用深度学习技术成功预测了数万个蛋白质的三维结构，为药物设计和疾病研究提供了重要支持。如今，随着ChatGPT等自然语言处理技术的不断发展，AI在生物领域的应用正日益数字化和智能化。英伟达医疗保健副总裁金伯利.鲍威尔表示，生物领域正在以“前所未有的规模和分辨率”日益数字化。这种数字化趋势为AI在药物发现中的应用提供了广阔的空间和无限的可能性。通过无监督和自我监督学习等技术手段，AI能够“思考”出人类难以做到的药物模型，并通过计算机模拟在药物世界中展现其独特魅力。四、AI药物发现的挑战与前景尽管AI在药物发现领域展现出巨大的潜力和优势，但其在实际应用中仍面临一些挑战和问题。例如，如何验证AI生成的药物设计的有效性和安全性？如何确保AI在药物研发过程中的可解释性和可预测性？这些都是AI药物发现领域需要关注和解决的问题。然而，随着技术的不断进步和应用场景的不断拓展，AI在药物发现领域的前景仍然十分广阔。未来，我们有理由相信AI将为我们带来更多创新药物和治疗方法，为人类的健康和福祉作出更大的贡献。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433341290"}